2017
Allograft transmission of hepatitis C during the window period: Weighing the new risks and costs in the era of donor shortage
Choe J, Merola J, Kulkarni S, Mulligan DC. Allograft transmission of hepatitis C during the window period: Weighing the new risks and costs in the era of donor shortage. Clinical Transplantation 2017, 31 PMID: 28643333, DOI: 10.1111/ctr.13022.Peer-Reviewed Original Research
2016
De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient
Cohen E, Mulligan D, Kulkarni S, Tichy E. De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient. American Journal Of Transplantation 2016, 16: 2753-2757. PMID: 27137752, DOI: 10.1111/ajt.13852.Peer-Reviewed Original ResearchConceptsRenal transplant recipientsTransplant recipientsHuman immunodeficiency virus–positive kidney transplant recipientHIV-positive renal transplant recipientsPositive renal transplant recipientsHIV-positive Black menActive antiretroviral agentsKidney transplant recipientsNew-onset diabetesHuman immunodeficiency virusImmunosuppressive regimensFirst transplantAntiretroviral agentsCalcineurin inhibitorsImmunodeficiency virusKidney donorsDrug interactionsTransplantRecipientsBlack menSuccessful casesDe novoBelataceptHypertensionHyperlipidemia
2013
Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation
Chakkera HA, Chang Y, Bodner JK, Behmen S, Heilman RL, Reddy KS, Mulligan DC, Moss AA, Khamash H, Katariya N, Hewitt WR, Pitta TL, Frassetto LA. Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation. Transplantation Proceedings 2013, 45: 137-141. PMID: 23375287, DOI: 10.1016/j.transproceed.2012.10.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Cohort StudiesFemaleGenetic VariationHumansImmunosuppressive AgentsIndians, North AmericanKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPharmacogeneticsPolymorphism, Single NucleotideTacrolimusTime FactorsConceptsKidney transplant recipientsTrough levelsTacrolimus dosingTransplant recipientsSingle nucleotide polymorphismsDaily tacrolimus doseLower tacrolimus dosesTacrolimus pharmacokinetic parametersTacrolimus trough levelsCaucasian kidney transplant recipientsStable dosesTacrolimus doseKidney transplantationTacrolimus dosesTacrolimus pharmacokineticsMonths posttransplantationOral clearanceTacrolimus clearanceDrug eliminationPharmacokinetic parametersVariant single nucleotide polymorphismsTacrolimusDrug metabolismPharmacokinetic studyLow dosage
2010
Outcomes After Simultaneous Pancreas and Kidney Transplantation and the Discriminative Ability of the C-peptide Measurement Pretransplant Among Type 1 and Type 2 Diabetes Mellitus
Chakkera HA, Bodner JK, Heilman RL, Mulligan DC, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Ray RM, Beck GL, Reddy KS. Outcomes After Simultaneous Pancreas and Kidney Transplantation and the Discriminative Ability of the C-peptide Measurement Pretransplant Among Type 1 and Type 2 Diabetes Mellitus. Transplantation Proceedings 2010, 42: 2650-2652. PMID: 20832562, PMCID: PMC3060052, DOI: 10.1016/j.transproceed.2010.04.065.Peer-Reviewed Original ResearchMeSH KeywordsAdultC-PeptideCreatinineDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic NephropathiesDiabetic RetinopathyFemaleFollow-Up StudiesGlycated HemoglobinGraft RejectionHumansKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPancreas TransplantationRetrospective StudiesSurvival AnalysisTissue DonorsConceptsEnd-stage renal diseaseType of diabetesC-peptideSimultaneous pancreasKidney transplantationPatient survivalGlutamic acid decarboxylase antibodiesType 2 diabetes mellitusDetectable C-peptideMean creatinine clearanceRenal Disease equationModification of DietBody mass indexC-peptide measurementsRegression survival analysisGlycosylate hemoglobinDiabetic ketoacidosisESRD patientsPancreas transplantationT2DM patientsCreatinine clearanceDecarboxylase antibodiesOral hypoglycemicsRenal replacementDiabetes mellitus
2009
Simultaneous Heart and Kidney Transplantation After Bridging With The CardioWest Total Artificial Heart
Jaroszewski DE, Pierce CC, Staley LL, Wong R, Scott RR, Steidley EE, Gopalan RS, DeValeria P, Lanza L, Mulligan D, Arabia FA. Simultaneous Heart and Kidney Transplantation After Bridging With The CardioWest Total Artificial Heart. The Annals Of Thoracic Surgery 2009, 88: 1324-1326. PMID: 19766830, DOI: 10.1016/j.athoracsur.2009.02.056.Peer-Reviewed Original ResearchMeSH KeywordsFollow-Up StudiesHeart FailureHeart TransplantationHeart, ArtificialHumansKidney Failure, ChronicKidney TransplantationMaleMiddle AgedProsthesis DesignConceptsCardioWest total artificial heartTotal artificial heartRenal failureEnd-stage renal failureTotal artificial heart implantationRisk of mortalityArtificial heart implantationArtificial heartSimultaneous heartCardiac transplantationKidney transplantationRelative contraindicationHeart implantationSuccessful treatmentTransplantationHeartContraindicationsPatientsFailureKidneyMortality
2004
Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy
Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: The impact of the MELD allocation policy. Gastroenterology 2004, 127: s261-s267. PMID: 15508092, DOI: 10.1053/j.gastro.2004.09.040.Peer-Reviewed Original ResearchConceptsNumber of patientsHepatocellular cancerHCC patientsWaiting listLiver transplantationDeceased donorsExcellent long-term survivalPost-MELD eraAdvanced stage diseaseLiver transplant candidatesLong-term survivalHigh mortality rateProgression of HCCHCC recipientsPosttransplant survivalStage diseaseTransplant candidatesUnited NetworkDonor organsLower incidenceMortality ratePatientsAdvanced stageEarly assessmentTransplantation